Burden of severe asthma by biologic use and eligibility: an analysis of the International Severe Asthma Registry

被引：0

作者：

Le, T. ^{[1
]}

Erhard, C. ^{[2
]}

Price, D. ^{[3
,4
,5
]}

Maslova, E. ^{[2
]}

Cook, B. ^{[6
]}

Quinton, A. ^{[7
]}

Katial, R. ^{[8
]}

Christoff, G. C. ^{[9
]}

Perez-De-Llano, L. ^{[10
]}

Carter, V ^{[3
,4
]}

Tran, T. N. ^{[1
]}

Tran, T.

机构：

[1] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[2] AstraZeneca, BioPharmaceut Med, Cambridge, England

[3] Observat & Pragmat Res Inst, Singapore, Singapore

[4] Optimum Patient Care Global, Cambridge, England

[5] Univ Aberdeen, Ctr Acad Primary Care, Div Appl Hlth Sci, Aberdeen, Scotland

[6] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[7] AstraZeneca, BioPharmaceut R&D, Cambridge, England

[8] AstraZeneca, Biopharmaceut Med, Global Med Resp, Gaithersburg, MD USA

[9] Med Univ Sofia, Fac Publ Hlth, Sofia, Bulgaria

[10] Hosp Univ Lucus August, Dept Resp Med, Lugo, Spain

来源：

关键词：

Asthma; -; management;

D O I：

10.1183/13993003.congress-2022.2143

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

2143

引用

页数：2